Completed
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
NCT00154388
- Conditions
- Adenocarcinoma, Adenoma, Adnexal Diseases, +121 more
- Locations
-
Not specified